All In Biotech

Drug Trial Radar · NCT00940784

Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

MPD-RC 108: Phase II, Randomized, Double-Blind, Placebo Controlled International Study of Clopidogrel and Aspirin for the Treatment of Polycythemia Vera

Last checked: Nov 19, 2026Latest source record: Nov 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 2009

Primary completion

Jan 2011

Study completion Jan 2011

Sponsor

Lead sponsor
Ronald HoffmanAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI)
First posted
Jul 16, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 81 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clopidogrel (Plavix) and aspirin are two antithrombotic agents (blood thinners) commonly used in patients with previous thrombotic events (stroke or heart attack). Thrombosis is the formation of a blood clot in a blood vessel. Patients with polycythemia vera are routinely treated with aspirin which has been shown to be effective in reducing their thrombotic risk. However, in polycythemia vera patients with previous thrombosis, a further benefit might be obtained by using the combination of aspirin and clopidogrel which is routinely used in patients with recent acute myocardial ischemia (reduced blood supply to the heart muscle). The study will assess whether this combination therapy greatly increases the risk of bleeding versus aspirin alone, if clopidogrel reduces biological factors that might lead to a stroke or heart attack, and whether a high number of patients with polycythemia vera are resistant to clopidogrel. Approximately 200 subjects will be enrolled to the Myeloproliferative Disorders-Research Consortium (MPD-RC) study in Europe and the United States with participation expected to last for 7 months (6 months of receiving study medication plus a 30 day follow-up visit).

Conditions

  • Polycythemia Vera

Interventions

  • Clopidogrel (Plavix)Drug

    Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea

  • PlaceboDrug

    Placebo, aspirin (81-100 mg qd) plus hydroxyurea

  • AspirinDrug

    81-100 mg qd

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the safety and efficacy of using Clopidogrel plus aspirin on Polycythemia Vera patientsTime frame: 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.